Bright Minds Biosciences (DRUG) Liabilities and Shareholders Equity (2020 - 2026)

Bright Minds Biosciences has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $227.8 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 478.79% year-over-year to $227.8 million; the trailing twelve-month figure through Mar 2026 stood at $392.2 million (up 334.67% YoY), and the FY2025 full-year result was $61.3 million, up 1270.81% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $227.8 million, up from $65.2 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $227.8 million in Q1 2026, with the low at $4.5 million in Q3 2024.
• Historically, Liabilities and Shareholders Equity has averaged $32.1 million across 5 years, with a median of $8.5 million in 2022.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity plunged 61.72% — and 2025, when it surged 1270.81%.
• Bright Minds Biosciences' Liabilities and Shareholders Equity stood at $8.5 million in 2022, then plunged by 40.55% to $5.1 million in 2023, then jumped by 726.38% to $41.8 million in 2024, then soared by 55.89% to $65.2 million in 2025, then soared by 249.52% to $227.8 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $227.8 million (Q1 2026), $65.2 million (Q4 2025), and $61.3 million (Q3 2025), per Business Quant data.